Monte Rosa rises as heart drug shows promise in early-stage trial

Shares of drug developer Monte Rosa Therapeutics GLUE.O rise 18.6% to $19 premarket

Co says its experimental pill, MRT-8102, sharply lowered inflammation in people at risk for heart disease in an early-stage trial

Co's MRT-8102 cut inflammation marker CRP by 85% in high-risk patients, says co

CRP is linked to heart disease; nearly all participants reached safe levels after 4 weeks - GLUE

Co says study enrolled 24 people with obesity and elevated CRP; drug worked across all doses

Co plans larger trial in patients with clogged arteries later this year - GLUE

As of last close, stock up ~2% over the past year